ArticleOncotarget2016

Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Fabio Giuseppe Liberante et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.